> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Janssen Says Spravato Tops Seroquel in Trial
- URL: https://www.fdaweb.com/janssen-says-spravato-tops-seroquel-in-trial/
- Published: 2022-11-23T12:00:00.000Z
- Updated: 2026-09-14T18:07:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153262

Janssen says results of the Phase 3b ESCAPE-TRD trial demonstrated that its Spravato (eskeamine nasal spray) had superior efficacy compared to Seroquel XR (quetiapine extended-release) in treatment-resistant major depressive disorder. A company [announcement](https://www.businesswire.com/news/home/20221123005062/en/SPRAVATO%C2%AE%E2%96%BC-esketamine-nasal-spray-data-from-the-phase-3b-ESCAPE-TRD-study-demonstrate-superior-efficacy-compared-to-quetiapine-extended-release-in-treatment-resistant-major-depressive-disorder1?ref=fdaweb.com) says that Spravato met its primary endpoint, demonstrating a superior efficacy in achieving remission at Week 8 compared to Seroquel XR. Janssen says the study also met its key secondary endpoint, demonstrating that not only did significantly more participants treated with Spravato compared to Seroquel achieve remission while on study treatment at Week 8, but they also remained relapse-free up to Week 32.